달테파린

용도

• Thromboembolic disease prophylaxis/treatment
• Thromboembolic disease prophylaxis/treatment
• Prophylaxis of coagulation disorders in colic patients
• Thromboembolic disease prophylaxis/treatment
• Thromboembolic disease prophylaxis/treatment

투여 방법

가능한 부작용

• Hemorrhage (unlikely but possible)
• Injection site hematomas or pain
• Allergic reactions
• Neurologic sequelae secondary to epidural or spinal hematomas

주의사항 및 금기

• Hypersensitivity to dalteparin, heparin, or pork products
• Active major bleeding
• Heparin-induced thrombocytopenia
• Thrombocytopenia associated with positive in vitro tests for anti-platelet antibodies in the presence of dalteparin
• Intramuscular (IM) or Intravenous (IV) administration
• Use cautiously in patients with significant renal dysfunction as drug accumulation could result. Use with extreme caution in patients with increased risk of hemorrhage. Do not administer via IM or IV routes; must be given via subcutaneous injection only. Cannot be used interchangeably with other LMWHs or heparin sodium, as dosages differ for each. May cause asymptomatic, fully-reversible increases in AST or ALT.

약물 상호작용

• Warfarin: Increased risk for hemorrhage
• Aspirin: Increased risk for hemorrhage
• Clopidogrel: Increased risk for hemorrhage
• Thrombolytic agents: Increased risk for hemorrhage

자주 묻는 질문